智通财经APP讯,亚宝药业(600351.SH)公告,公司控股孙公司苏州亚宝药物研发有限公司(简称“苏州亚宝”)收到了国家药品监督管理局核准签发的SY-005注射液新增适应症的《药物临床试验批准通知书》,批准了SY-005注射液针对脑胶质瘤术后神经功能缺损开展临床试验的申请。
SY-005是一种创新型的重组蛋白,2018年11月获得治疗脓毒症适应症的《药物临床试验批准通知书》,目前该适应症处于Ⅱ期临床试验阶段。SY-005注射液本次申请增加的适应症为脑胶质瘤术后神经功能缺损。
智通财经APP讯,亚宝药业(600351.SH)公告,公司控股孙公司苏州亚宝药物研发有限公司(简称“苏州亚宝”)收到了国家药品监督管理局核准签发的SY-005注射液新增适应症的《药物临床试验批准通知书》,批准了SY-005注射液针对脑胶质瘤术后神经功能缺损开展临床试验的申请。
SY-005是一种创新型的重组蛋白,2018年11月获得治疗脓毒症适应症的《药物临床试验批准通知书》,目前该适应症处于Ⅱ期临床试验阶段。SY-005注射液本次申请增加的适应症为脑胶质瘤术后神经功能缺损。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.